AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25046946 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) 50 microg, thrice per week for 24 weeks
Number of subjects: 193
Study 25046946 — intervention group
Group type: COMPARATOR
Intervention: Xiaoyao Powder (XYP) combined with Interferon-alpha (IFN-alpha)
Number of subjects: 193
Study 22682610 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-walking with smaller walk ratio (shorter steps, faster cadence)
Number of subjects: 176
Study 22682610 — intervention group
Group type: EXPERIMENTAL
Intervention: Change to fast-walking with greater reduction in walk ratio (smaller increase in step length, larger increase in cadence)
Number of subjects: 176
Study 22682610 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastest quarter of gait speed during fast-walking
Number of subjects: 176
Study 20647098 — intervention group
Group type: EXPERIMENTAL
Intervention: F file for 30 seconds
Number of subjects: 40
Study 20647098 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoActivator system for 30 seconds
Number of subjects: 40
Study 20647098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic irrigation for 30 seconds
Number of subjects: 40
Study 20647098 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% NaOCl irrigation for 30 seconds
Number of subjects: 40
Study 18848553 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg every other week
Number of subjects: 778
Study 18848553 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg weekly
Number of subjects: 778
Study 18848553 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab combined (every other week and weekly)
Number of subjects: 778
Study 18848553 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab every other week
Number of subjects: 778
Study 18848553 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab weekly
Number of subjects: 778
Study 18848553 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab combined
Number of subjects: 778
Study 18848553 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 778
Study 16038684 — intervention group
Group type: EXPERIMENTAL
Intervention: NK1 antagonist GR205171 (5 mg)
Number of subjects: 36
Study 16038684 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg)
Number of subjects: 36
Study 16038684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12871686 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (80 g/kg intravenous injection 5 min before ballooning)
Number of subjects: 44
Study 12871686 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 44
Study 12871686 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 44
Study 10475141 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinda‐saar 600 (test preparation, 600 mg clindamycin)
Number of subjects: 20
Study 10475141 — intervention group
Group type: COMPARATOR
Intervention: Sobelin 300 (reference preparation, 300 mg clindamycin)
Number of subjects: 20
Study 10475141 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 20
Study 8870155 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed alternative procedure to the two-sided test
Number of subjects: 0
Study 8870155 — intervention group
Group type: COMPARATOR
Intervention: Two-sided test
Number of subjects: 0
Study 1831340 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intravenous administration of CI-898 at 15 mg/m2
Number of subjects: 22
Study 1831340 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day intravenous administration of CI-898 starting at 10 mg/m2/day
Number of subjects: 22
Study 1831340 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day intravenous administration of CI-898
Number of subjects: 22
Study 1831340 — intervention group
Group type: EXPERIMENTAL
Intervention: Single treatment of CI-898
Number of subjects: 22
Study 1831340 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day treatment of CI-898
Number of subjects: 22
Study 7043711 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopoietin
Number of subjects: 36
Study 7043711 — intervention group
Group type: COMPARATOR
Intervention: Levamisole
Number of subjects: 36
Study 7043711 — intervention group
Group type: COMPARATOR
Intervention: Penicillamine
Number of subjects: 36
Study 30348586 — intervention group
Group type: EXPERIMENTAL
Intervention: teriflunomide 14 mg
Number of subjects: 0
Study 30348586 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 29901443 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable everolimus‐eluting vascular scaffolds (BVS)
Number of subjects: 95
Study 29901443 — intervention group
Group type: COMPARATOR
Intervention: Drug‐eluting stents with bioabsorbable polymers (BP‐DES)
Number of subjects: 95
Study 27598678 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF/GB (beclometasone dipropionate 100 μg, formoterol fumarate 6 μg, glycopyrronium bromide 12.5 μg)
Number of subjects: 1368
Study 27598678 — intervention group
Group type: COMPARATOR
Intervention: BDP/FF (beclometasone dipropionate 100 μg, formoterol fumarate 6 μg)
Number of subjects: 1368
Study 24535621 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH‐s group (standard LMWH program, initiated 12 hours after wound closure)
Number of subjects: 210
Study 24535621 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH‐p group (delayed LMWH, initiated 24 hours after wound closure)
Number of subjects: 210
Study 24535621 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH‐s group
Number of subjects: 210
Study 24535621 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH‐p group
Number of subjects: 210
Study 22515897 — intervention group
Group type: EXPERIMENTAL
Intervention: NovaMin paste treatment for 5 minutes (Group A)
Number of subjects: 48
Study 22515897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (0.5 w, 10 Hz, and 50 mJ) (Group B)
Number of subjects: 48
Study 22515897 — intervention group
Group type: EXPERIMENTAL
Intervention: NovaMin followed by Nd:YAG laser (Group C)
Number of subjects: 48
Study 22515897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser followed by NovaMin (Group D)
Number of subjects: 48
Study 20560802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg daily for a maximum of 4 weeks)
Number of subjects: 88
Study 20560802 — intervention group
Group type: COMPARATOR
Intervention: Control group (pain-relieving therapy only)
Number of subjects: 88
Study 17697874 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesaglitazar 3 mg
Number of subjects: 58
Study 17697874 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone 45 mg
Number of subjects: 58
Study 17697874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 15578172 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐omeprazole (20 mg)
Number of subjects: 24
Study 15578172 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐omeprazole (20 mg)
Number of subjects: 24
Study 15578172 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic omeprazole (20 mg)
Number of subjects: 24
Study 15578172 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐omeprazole (40 mg)
Number of subjects: 24
Study 15578172 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐omeprazole (40 mg)
Number of subjects: 24
Study 15578172 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic omeprazole (40 mg)
Number of subjects: 24
Study 12731719 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group
Number of subjects: 0
Study 12731719 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9933654 — intervention group
Group type: EXPERIMENTAL
Intervention: 153Sm-EDTMP at a dose of 37 MBq/kg (group I)
Number of subjects: 105
Study 9933654 — intervention group
Group type: EXPERIMENTAL
Intervention: 153Sm-EDTMP at a dose of 18.5 MBq/kg (group II)
Number of subjects: 105
Study 9933654 — intervention group
Group type: COMPARATOR
Intervention: Analgesics
Number of subjects: 105
Study 9933654 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky score (KS)
Number of subjects: 105
Study 9933654 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer subgroup
Number of subjects: 105
Study 9933654 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cell and platelet counts
Number of subjects: 105
Study 9933654 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver function tests
Number of subjects: 105
Study 9933654 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response
Number of subjects: 105
Study 7476067 — intervention group
Group type: EXPERIMENTAL
Intervention: Accommodating resistance device (ARD) training: 3-5 sets of 10 maximal concentric actions.
Number of subjects: 12
Study 7476067 — intervention group
Group type: COMPARATOR
Intervention: Weight resistance device (WRD) training: 3-5 sets of 8-12 coupled eccentric/concentric actions to volitional failure (8-12 RM).
Number of subjects: 12
Study 2105373 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 10
Study 6777315 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic penicillin
Number of subjects: 0
Study 6777315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31781933 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial enteral nutrition (PEN)
Number of subjects: 25
Study 31781933 — intervention group
Group type: COMPARATOR
Intervention: Exclusive enteral nutrition (EEN)
Number of subjects: 25
Study 31184255 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training (WBT)
Number of subjects: 11293
Study 31184255 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support system (CCDSS)
Number of subjects: 11293
Study 31184255 — intervention group
Group type: EXPERIMENTAL
Intervention: CCDSS and WBT (BOTH)
Number of subjects: 11293
Study 31184255 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 11293
Study 31184255 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall vaccination rate
Number of subjects: 11293
Study 26603219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hollyhock leaf compress combined with warm and cold compress
Number of subjects: 40
Study 26603219 — intervention group
Group type: COMPARATOR
Intervention: Routine interventions and warm compress before nursing and cold compress after nursing
Number of subjects: 40
Study 25389218 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD-assisted psychotherapy
Number of subjects: 10
Study 23533289 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D IW fast SE
Number of subjects: 100
Study 23533289 — intervention group
Group type: COMPARATOR
Intervention: 3D balanced FFE
Number of subjects: 100
Study 23533289 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D fast SE
Number of subjects: 100
Study 21627397 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight children
Number of subjects: 89
Study 21627397 — intervention group
Group type: COMPARATOR
Intervention: Non-overweight children
Number of subjects: 89
Study 18435693 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-h recovery training (REC)
Number of subjects: 11
Study 18435693 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h active recovery
Number of subjects: 11
Study 16506459 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest autograft (ICAG) fusion
Number of subjects: 100
Study 16506459 — intervention group
Group type: COMPARATOR
Intervention: Rectangular titanium cage (RTC) fusion
Number of subjects: 100
Study 12690546 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (4.5 g every 8 h)
Number of subjects: 130
Study 12690546 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (2 g once daily plus gentamicin 5 mg/kg once daily)
Number of subjects: 130
Study 10854015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint interval running programme (n = 12)
Number of subjects: 39
Study 10854015 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cycle ergometer programme (n = 13)
Number of subjects: 39
Study 10854015 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 39
Study 9176069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat (10% Intralipid)
Number of subjects: 23
Study 9176069 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 23
Study 1489202 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour infusions of amphotericin B (AMB) at doses ranging from 0.27 to 0.89 mg/kg
Number of subjects: 27
Study 1489202 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour infusions of amphotericin B (AMB)
Number of subjects: 27
Study 3156798 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nitrendipine
Number of subjects: 13
Study 3156798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 29973601 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent word list condition
Number of subjects: 240
Study 29973601 — intervention group
Group type: COMPARATOR
Intervention: Randomized word list condition
Number of subjects: 240
Study 29973601 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-subject word list condition
Number of subjects: 240
Study 26372517 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BB-12 (BB-12) administered twice a day (daily dose of BB-12 10 billion colony-forming units) until the age of 2 years.
Number of subjects: 109
Study 26372517 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 109
Study 25981123 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (±glulisine)
Number of subjects: 923
Study 25981123 — intervention group
Group type: COMPARATOR
Intervention: Premixed insulin
Number of subjects: 923
Study 23036264 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 3 weeks
Number of subjects: 51
Study 23036264 — intervention group
Group type: COMPARATOR
Intervention: Placebo-CPAP
Number of subjects: 51
Study 21765220 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip strengthening and movement education program 3 times per week for 6 weeks, including single-leg squat training with neuromuscular reeducation.
Number of subjects: 20
Study 21765220 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention, maintained current running distance).
Number of subjects: 20
Study 19332365 — intervention group
Group type: EXPERIMENTAL
Intervention: Take Charge of Your Life (TCYL) program
Number of subjects: 19329
Study 19332365 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19329
Study 16707077 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol trinitrate (GTN) patches
Number of subjects: 156
Study 16707077 — intervention group
Group type: COMPARATOR
Intervention: Standard beta2 agonist
Number of subjects: 156
Study 15265423 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with omeperazole, clarithromycin (CLA), and amoxycillin (AMO) for one week (CLA group)
Number of subjects: 192
Study 15265423 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with omeperazole, metronidazole (MET), and amoxycillin (AMO) for two weeks (MET group)
Number of subjects: 192
Study 15265423 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-treatment with CLA triple therapy for one week after failure of MET therapy
Number of subjects: 192
Study 15265423 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-treatment with increased doses of CLA and longer treatment course after failure of CLA therapy
Number of subjects: 192
Study 15265423 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetra therapy with omeperazole, colloidal bismuth subcitrate (CBS), furazolidone (FUR), and AMO after failure of re-treatment
Number of subjects: 192
Study 15265423 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA triple therapy for children who were Hp eradicated and followed for 3 years
Number of subjects: 192
Study 11471613 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted gadolinium chelate (0.1 mmol/kg BW)
Number of subjects: 20
Study 11471613 — intervention group
Group type: COMPARATOR
Intervention: Undiluted gadolinium chelate (0.1 mmol/kg BW)
Number of subjects: 20
Study 9306935 — intervention group
Group type: EXPERIMENTAL
Intervention: CHROMagar Candida (CA)
Number of subjects: 1784
Study 9306935 — intervention group
Group type: COMPARATOR
Intervention: Sabouraud dextrose agar (SDA)
Number of subjects: 1784
Study 8028874 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 760
Study 8028874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 760
Study 8028874 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications with hyaluronidase
Number of subjects: 760
Study 8028874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study 2605440 — intervention group
Group type: EXPERIMENTAL
Intervention: Test A (exercise at 70% VO2 max)
Number of subjects: 9
Study 2605440 — intervention group
Group type: EXPERIMENTAL
Intervention: Test B (exercise at fixed workload of 140 W)
Number of subjects: 9
Study 817384 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% solution of sodium cromoglycate (S.C.G.)
Number of subjects: 0
Study 817384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30946888 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 10 mg/ml
Number of subjects: 220
Study 30946888 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 40 mg/ml
Number of subjects: 220
Study 30946888 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 100 mg/ml
Number of subjects: 220
Study 30946888 — intervention group
Group type: COMPARATOR
Intervention: Monthly intravitreal ranibizumab 0.5 mg
Number of subjects: 220
Study 29165105 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based educational program including motivational interviewing, a booklet, and daily SMS.
Number of subjects: 104
Study 29165105 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 104
Study 25467995 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral core training for eight weeks
Number of subjects: 16
Study 25467995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 16
Study 25268241 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene
Number of subjects: 0
Study 25268241 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene plus face masks
Number of subjects: 0
Study 25268241 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22210302 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month treadmill training program
Number of subjects: 64
Study 22210302 — intervention group
Group type: COMPARATOR
Intervention: Stretching program
Number of subjects: 64
Study 20806131 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated without pretreatment (intervention arm)
Number of subjects: 0
Study 20806131 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiation therapy with subsequent surgery (control arm)
Number of subjects: 0
Study 19046107 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (upfront)
Number of subjects: 0
Study 19046107 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (5-year regimen)
Number of subjects: 0
Study 16401152 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) applied at 100% of motor threshold, frequency of 10 Hz, 40 trains at 5 seconds per train (2000 pulses per session), sessions averaged 1 to 2 per week for 6 months to 6 years
Number of subjects: 10
Study 12566906 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) 10,000 U thrice weekly s.c.
Number of subjects: 144
Study 12566906 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 144
Study 10392416 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum‐A toxin (2 units per kilogram)
Number of subjects: 10
Study 9078647 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dentifrice and oral rinse containing sanguinaria extract and zinc chloride
Number of subjects: 34
Study 9078647 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice and oral rinse
Number of subjects: 34
Study 8103272 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporin A (8% w/v) with penetration enhancers (propylene glycol 18% and azone 2%)
Number of subjects: 5
Study 8103272 — intervention group
Group type: COMPARATOR
Intervention: Vehicle comprising olive oil with penetration enhancers
Number of subjects: 5
Study 8103272 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporin A (8% w/v)
Number of subjects: 5
Study 3714757 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tiropramide
Number of subjects: 60
Study 3714757 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg trimebutine maleate
Number of subjects: 60
Study 3714757 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg octilonium bromide
Number of subjects: 60
Study 30203841 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag 20 mg daily for 14 days
Number of subjects: 92
Study 30203841 — intervention group
Group type: COMPARATOR
Intervention: Avatrombopag (1, 3, 10, 20, 50, 75 and 100 mg)
Number of subjects: 92
Study 30203841 — intervention group
Group type: COMPARATOR
Intervention: Avatrombopag (3, 10 and 20 mg)
Number of subjects: 92
Study 26321236 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-site biventricular pacing
Number of subjects: 126
Study 26321236 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-site LV only pacing
Number of subjects: 126
Study 26321236 — intervention group
Group type: COMPARATOR
Intervention: Non-implanted control
Number of subjects: 126
Study 26321236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled pacing therapy
Number of subjects: 126
Study 23889105 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g intravenous Cefazoline administered prior to skin incision
Number of subjects: 100
Study 23889105 — intervention group
Group type: COMPARATOR
Intervention: 2 g intravenous Cefazoline administered immediately after cord clamping
Number of subjects: 100
Study 22134627 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysporin Triple ointment (P(3))
Number of subjects: 201
Study 22134627 — intervention group
Group type: COMPARATOR
Intervention: mupirocin
Number of subjects: 201